Health Care • Biotechnology: Pharmaceutical Preparations
$558.88 ▲ +18.88
(+3.50%)
MKT CAP: $136.87B • VOL: 3.03M
52W L $403 52W H $564
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$469
MEDIAN
$626
MEAN
$637
HIGH
$760
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE VRTX TAPE
VRTX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $676.24 | $642.71 | 2025-02-14 | $508.58 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $704.19 | $659.48 | 2025-02-06 | $525.35 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $637.12 | $614.77 | 2025-01-29 | $536.52 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $570.06 | — | 2025-01-17 | $547.70 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $491.81 | $530.94 | 2025-01-09 | $497.40 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $665.07 | $581.24 | 2024-12-18 | $486.23 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $542.11 | $564.47 | 2024-12-04 | $519.76 | -4.3% | 48% | C |